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Current standard-of-care therapy for diffuse large B cell lymphoma (DLBCL) results in up to 
40% of patients who either relapse or develop refractory disease. In this setting, further 
therapeutic improvements are needed. Here, we analyzed the in vitro effects of the combination 
of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This 
combination enhanced histone acetylation and double strand DNA breaks resulting in an 
additive to synergistic cytotoxic effect in both ABC- and GCB-type DLBCL cells, independently 
of their TP53 mutational status. These results support the rationale for considering 




Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL) 
that comprises different entities with specific genetic alterations and heterogeneous clinical 
outcome. Gene expression profiling revealed 3 different molecular subtypes based on cell of 
origin: germinal center B-cell-like DLBCL (GCB-DLBCL), activated B-cell-like DLBCL (ABC-
DLBCL), and mediastinal or unclassified type [1]. Although most patients respond to standard 
treatment with immunochemotherapy (eg, R-CHOP), 40% remain refractory or relapse, 
especially within the ABC subgroup [2]. Our increasing knowledge of tumor biology and the 
identification of targetable pathways can enable the exploration of more effective treatment 
strategy approaches in DLBCL. 
Bendamustine hydrochloride (BEN) was developed as a molecule with alkylator and 
antimetabolite structure. Compared to other conventional alkylators, such as 
cyclophosphamide, BEN has a unique mechanistic profile that includes induction of single and 
double-strand DNA (dsDNA) breaks, activation of DNA damage stress response and apoptosis, 
inhibition of mitotic checkpoints, and induction of mitotic catastrophe [3]. Moreover, BEN shows 
limited cross-resistance to other alkylating agents and has demonstrated clinical activity as 
single-agent therapy or in combination with other antineoplastic agents in relapsed indolent 
NHL, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), including patients 
refractory to alkylating or purine analog agents [4,5]. At present time, there is limited data 
available on the efficacy of BEN in aggressive lymphomas, including DLBCL [6-9]. 
Vorinostat (VOR) is a histone deacetylase inhibitor (HDACi). HDACis regulate histone and non-
histone protein acetylation, playing a critical role in the modulation of gene expression. Although 
their specific mechanism of action is still unclear, HDACis exert several antitumor effects, 
including induction of apoptosis and differentiation, cell cycle arrest, regulation of tumor 
immunology, tumor suppressor gene transcription, and angiogenesis inhibition [10]. VOR has 
been approved for the treatment of cutaneous T-cell lymphoma [11] and is currently under study 
in other types of lymphoma [12-15]. Single-agent vorinostat has shown modest activity in 
relapsed/refractory indolent NHL (overall response rate -ORR- 29%), although higher response 
rates were achieved in patients with follicular histology (ORR 47%). In aggressive B-cell 
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lymphomas, a phase II trial has shown very modest activity for single-agent vorinostat in 
patients with relapsed DLCBL with only 6% of cases responding [15]. Preclinical studies have 
found that HDACis exert their broadest activity in combination with other agents, especially 
when these combinations are based on the rationale of their mechanistic interaction [16-18]. 
Thereby, clinical trials using vorinostat plus rituximab or other novel targeted agents have been 
carried out in some lymphoma types [19,20]. 
The present study was designed to explore in vitro the interaction of BEN and VOR in DLBCL. 
We hypothesized that, besides its wide antitumor effects, VOR would promote an open 
chromatin conformation that might allow extensive BEN accessibility, potentially enhancing the 
direct DNA damage. To assess this approach, we used two GCB-type and two ABC-type 
DLBCL cell lines; one of each type harbored known pathogenic TP53 mutations, which affect 
20% of DLBCL patients and are an independent prognostic factor in DLBCL [21]. 
MATERIALS AND METHODS 
Cell Lines and Primary Cells 
The DLBCL cell line OCI-Ly19 (GCB, TP53wt) was purchased from the DSMZ (Braunschweig, 
Germany). The SU-DHL-6 (GCB, TP53mut), RC-K8 (ABC, TP53wt) and U-2932 (ABC, TP53mut) 
were kindly provided by Dr D. Dominguez (Columbia University, NY, USA). Primary cells from a 
patient with GCB- and from another with ABC-DLBCL (according to Hans’ algorithm [22]) were 
collected by heparinized-RPMI perfusion of fresh neoplastic lymph node biopsies and were 
stored cryopreserved in liquid nitrogen until use. Both patients gave their signed informed 
consent. Biological samples were obtained from Parc de Salut MAR Biobank 
(MARBiobanc) Barcelona. Cell lines and primary cells were grown in RPMI 1640 medium 
containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine and 50 µg/ml penicillin-
streptomycin (GIBCO, Carlsbad, CA, USA) at 37°C in a humidified atmosphere containing 5% 





VOR (suberoylanilide hydroxamic acid, SAHA) was purchased from Selleck Chemicals 
(Houston, TX, USA) and BEN was provided by Levact (Mundipharma Pharmaceuticals, 
Cambridge, UK). VOR was dissolved in 100% dimetil sulfoxide (DMSO) to a stock concentration 
of 50 mM and BEN was dissolved in physiological saline at 5mg/mL. 
Analysis of Cell Viability and Apoptosis by Flow Cyt ometry after Drug Exposure 
Cell lines were incubated (0.5-1x106/mL) with different concentrations of BEN (25-100 µM) 
and/or VOR (0.3-5 µM). Cell viability and apoptosis were evaluated by annexin-V staining; the 
50% inhibitory concentration (IC50) was defined as the concentration of drug required to reduce 
cell viability by 50%. Briefly, after 24 and 48h, cells were washed with annexin binding buffer 
(100 mM HEPES, 280 mM NaCl and 5 mM CaCl2, pH 7.4), resuspended in 400 µL of fresh 
buffer and labeled for 15 minutes in the dark with annexin-V-FITC (eBioscience, San Diego, CA, 
USA) at a 1:200 final dilution. The DAPI nucleic acid stain (Invitrogen, Carlsbad, CA, USA) was 
added (1:4000) at the time of the analysis. Each condition was assessed in duplicates and data 
were confirmed by at least three independent experiments. 
Primary cells were analyzed at 24h. For cell population selection an anti-CD3 (1:200) and anti-
CD19 (1:40) antibodies (Becton Dickinson, Franklin Lakes, NJ, USA) were used.  
For each analysis, at least 10,000 events were recorded with a BD LSR II flow cytometer 
(Becton Dickinson). Double-negative population was considered viable cells, while both 
annexin-V-positive/DAPI-negative and annexin-V-positive/DAPI-positive populations were 
considered apoptotic committed cells. 
Western Blot Analysis 
Proteins were extracted in RIPA buffer (Sigma, St. Louis, MO, USA) and quantified using 
Bradford assay (Bio-Rad, Hercules, CA, USA). Thirty micrograms of proteins were separated on 
10-15% SDS-PAGE gel and transferred to Immobilion-P PVDF membranes (Millipore, Hayward, 
CA) and incubated with primary antibodies for anti-acetyl-histone H3 (06-599; 1:20000, 
Millipore), anti-phospho-H2A.X (07-164, 1:500, Millipore), anti-p53 (NCL-L-p53-DO; 1:1000, 
Novocastra, Newcastle, UK), anti-poli (ADP-ribose) polymerase (PARP, 11 835 238 001; 
1:2000, Roche, Switzerland) and α-tubulin (CP06; 1:200, Millipore) (used  as internal control). 
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Appropiate HRP-conjugated secondary antibody (P0260 or P0448; 1:2000; DAKO, Glostrup, 
Denmark) was used to reveal. Signals were developed with enhanced chemiluminiscence 
(Pierce, Rockford, IL).  
Quantitative Real-Time PCR Analysis Of p21 WAF1/CIP1 Gene Expression 
After 48h of treatment, total cellular RNA from 0.5x106 cells was extracted using Trizol 
(Invitrogen).High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA, USA), was used for reverse transcription (RT) reactions following the manufacturers’ 
protocols. Primers and probes were purchased from Applied Biosystems (Hs00355782_m1) 
and analyzed using a 7900 HT Real-Time PCR System (Applied Biosystems). GUS, β-actine 
and beta-2-microglobuline were used as internal controls. Relative quantification was calculated 
using 2-∆∆Ct. 
Cell Proliferation Assay  
Cells were harvested into 96-well plates (0.1x106 per well) and treated with different doses of 
BEN (5, 10, 25, 50, 100 µM) and VOR (0.5, 1, 2, 2.5, 5 µM) alone and in all possible 
combinations. The CellTiter proliferation assay (Promega, Madison, WI) was used according the 
manufacturer’s instructions. The absorbance was measured at 490 nm with an Infinite 200 PRO 
microplate reader (Tecan, Durham, NC). 
 
Statistical Analyses 
Means were compared between two groups using a 2-sided Student t-test, using GraphPad 
Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). The proliferation and apoptosis data 
were shown as mean ± SEM of three independent replicates. To study the interaction between 
the two drugs we used Bliss independence model. Bliss independence is the index for 
calculating the expected dose-response relationship for drug combination therapy as compared 
to mono-therapy, focusing on treatment effect enhancement. Given the two drugs BEN and 
VOR, both inhibiting tumor growth: BEN at dose b inhibits Yb % of tumor growth and VOR at 
dose v inhibits Yv % of tumor growth. If BEN and VOR work independently, the combined 
percentage inhibition Ybv,P can be predicted using the complete additivity of probability theory as 
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Ybv,P =Yb+Yv-YbYv. The interaction of each combination of the two drugs can be described by 
calculating the difference between the predicted % of growth inhibition, Ybv,P, and the observed 
% of growth inhibition, Ybv,O (∆Y=Ybv,O-Yvb,P). Therefore, Bliss synergy and antagonism were 
concluded when ∆Y and its 95% confidence interval (CI) were>0 and <0, respectively, and in 
case where the 95% CI of ∆Y would include 0, the conclusion was Bliss independence or 
additive interaction [23]. 
RESULTS 
BEN and VOR Individually Exert  Cytotoxic Effect in  DLBCL Cell Lines 
OCI-Ly19 (GCB, TP53wt), SU-DHL-6 (GCB, TP53mut), RC-K8 (ABC, TP53wt) and U-2932 (ABC, 
TP53mut) cells were exposed during 48 hours to increasing doses of BEN or VOR. 
Concentrations of BEN ranging from 25 to 100 µM and of VOR ranging from 0.3 to 2.5 µM were 
used. IC50 values were calculated from data obtained from the annexin-V assay performed by 
flow cytometry (Figure 1 and Table I). For all cell lines, both BEN and VOR alone caused a 
decrease in cell viability in a dose-dependent manner. Each cell line showed a different 
sensitivity to BEN although no association was found with DLBCL subtypes, whereas GCB-
DLBCL cell lines showed a higher cytotoxic response to VOR than ABC-DLBCL subtype 
(P<0.001). 
BEN and VOR In Combination Treatment 
For the combination assays, the IC50 of BEN and a fixed dose of VOR of 2.5 µM were used. IC50 
concentrations and achieved toxicity for each cell type are listed in Table I. Both drugs were 
added simultaneously. As shown in Figure 2A, the addition of VOR resulted in a significant 
increase of cytotoxicity compared to that obtained with BEN alone. The Bliss model for drug 
combination study indicated that the cytotoxic effects were slightly synergistic for the SU-DHL-6 
and the RC-K8 cell lines and additive for the other two cell lines at the doses tested (Table I). 
Effect of the Sequence of Treatment 
To explore a potential enhanced cytotoxic effect of pretreating cells with VOR, we assessed 
different sequences of treatment. However, the addition of BEN 24 or 72 h after VOR did not 
8 
 
increase the cytotoxic effect compared to the concomitant exposure to both drugs (data not 
shown). 
Effects in Primary Cells 
The effects of BEN and VOR, alone and in combination, were studied in the subpopulation of 
lymph node B cells (CD3-, CD19+) from 2 DLBCL (1 GCB and 1 ABC) patients. At 24h, both 
BEN and VOR showed a dose-dependent effect on cell viability. The drug combination induced 
a higher cytotoxic response comparing with the individual effects of BEN and VOR alone drugs 
but no significant differences in cytotoxicity were observed according to ABC/GCB subtype 
(Figure 2B). 
dsDNA Breaks and Apoptosis Induction   
To study the ability of BEN and VOR to induce DNA damage, H2A.X phosphorylation was 
analyzed as an indirect marker of dsDNA breaks. As shown in Figure 3, no signal was detected 
in untreated cells after 48 hours incubations, whereas both BEN and VOR induced dsDNA 
breaks. When cells were treated with the combination of both drugs, a 1.6- to 5.5-fold increase 
in H2A.X phosphorylation was seen compared to BEN exposure alone. 
The enzymatic cleavage of PARP protein, a classic marker for caspase 3-induced apoptosis, 
was evaluated by western blot (Figure 3). After 48h of BEN and/or VOR treatment, the 85-kDa 
corresponding to cleaved PARP was detected. PARP cleavage was slightly higher after BEN 
treatment than after the combination treatment. 
Histone H3 Acetylation 
Since histone H3 is one of the main substrates of HDACis, H3 acetylation was assessed by 
western blot. Hyperacetylation of histone H3 was observed following VOR treatment (Figure 3). 
Interestingly, BEN alone induced only weak detectable levels of acetylated H3 in two cell lines, 
whereas the combination of BEN and VOR resulted in a 2.7- to 5.6-fold increase of histone H3 
acetylation in three out four cell lines compared to VOR treatment alone. 
p53 and p21 Expression 
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In the western blot study, after BEN treatment, a 1.3- and a 3.3-fold increase of p53 were 
observed in the OCI-Ly19 and RC-K8 TP53-wild-type cells, respectively (Figure 4A), whereas 
VOR decreased p53 levels in all cells. After the combination treatment, only the RC-K8 cells 
showed a 2.3 fold increase of p53, while the other cells showed slightly decreased p53 
expression. We next examined p21WAF1/CIP1 expression by quantitative PCR. BEN treatment 
triggered a notable increase in p21WAF1/CIP1 in both TP53-wild-type cells OCI-Ly19 and RC-K8, 
matching the p53 results. VOR treatment enhanced p21WAF1/CIP1 expression in the two GCB-
subtype cell lines OCI-Ly19 and SU-DHL-6, while it remained invariable in ABC-subtype cells. 
After the BEN-plus-VOR combination treatment, p21WAF1/CIP1 increased in the OCI-Ly19 and SU-
DHL-6 cells and slightly in the RC-K8 cells. 
DISCUSSION 
As a complex multi-hit disease, DLBCL shows a wide range of clinical and molecular features 
that result in heterogeneous clinical responses. Distinct pathogenic pathways have been 
described to be altered in these patients, supporting the efforts to explore new drug combination 
strategies [24]. Phase I and II clinical trials in DLBCL patients containing BEN [8,9,25,26] or 
VOR [14,15] have been reported, showing diverse responses. Despite of BEN has shown 
promising results, VOR in monotherapy has shown limited activity in DLBCL patients. However, 
there are no clinical trials using the combination of both drugs and the mechanisms of action of 
both drugs alone or in combination have been poorly explored in DLBCL. [3,4,16,27-31].  
In our study, we have analyzed the cytotoxic effects of BEN and VOR as single agents and in 
combination in DLBCL cells and we have studied the mechanisms involved in this process. At 
clinically achievable concentrations, both BEN and VOR exerted single-agent cell killing activity 
in a dose- and time-dependent manner against GCB and ABC-DLBCL cell lines as well as in 
patients’ cells in ex vivo cultures. Interestingly, GCB-type cell lines were more sensitive to VOR 
than ABC-type cells, whereas no difference in sensitivity was observed to BEN treatment. This 
differential response to VOR is opposed to the results obtained in a prior report using the pan-
HDACi belinostat with some of the same cell lines used in our study, which found that cells’ 
sensitivity did not depend on the DLBCL-subtype [32]. Hyperacetylation of NF-κB in response to 
HDACis has been proposed to cause an anti-apoptotic effect [10,16], which would explain the 
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lower sensitivity to VOR in ABC-DLBCL cell lines, that are known to depend on the constitutive 
activation of the NF-κB pro-survival factor, in contrast to the GCB-DLBCL type [33]. 
Novel targeted therapies such as BCR inhibitors are known to affect ABC-DLBCL cell by 
affecting the NF-kB signaling pathway. For instance, ibrutinib, a BTK-inhibitor, in combination 
with VOR have shown synergistic effect in mantle cell lymphoma cell lines [19]. Moreover, VOR 
potentiates the activity of carfilzomib, a proteasome inhibitor, in GC- and ABC-DLBCL cells, 
including bortezomib-resistant cells [16]. However, the activity of BEN in combination with VOR 
in DLBCL subtypes is limited and deserves further investigation. Other specific agents such as 
monoclonal antibodies against CD20 can be used to target B-cell lymphomas. Of interest, a 
phase 2 study using a combination of rituximab plus VOR has shown promising efficacy in 
patients with indolent non-Hodgkin lymphoma [20]. This combination might be also useful for 
patients with DLBCL but clinical trials are still ongoing. 
In order to explore the contribution of an HDACi to BEN mode of action, a fixed dose of VOR 
was added. The addition of a 2.5 µM dose of VOR [34]  to the BEN treatment of DLBCL cell 
lines resulted in a significantly higher toxicity comparing with BEN treatment as single-agent 
(Figure 1). This increased toxic effect was synergistic in two cell lines (SUDHL6 and RC-K8), 
while it was more likely to be independent or additive in the others, according to the Bliss 
independence model. Apart from their single-agent antitumor effects, HDACis act remodeling 
chromatin to a loosen conformation [10], potentially making the DNA more accessible to 
damaging agents. Here, we show a striking increase of phosphorylated-H2A.X (P-H2A.X) levels 
when co-treating cells with BEN and VOR, thus demonstrating enhanced DNA damage [35]. 
Regarding this, prior reports have provided evidence about the importance of the sequence of 
treatment when combining HDACis with DNA-damaging agents [36-39], but in our study VOR 
pre-treatment exposure did not enhance BEN cytotoxic effect compared to the addition of both 
drugs concomitantly, in accordance with a previous study in leukemia cells of our group [40]. On 
the other hand, in this study we have demonstrated that the ability of VOR to promote 
acetylation was enhanced when cells were treated together with BEN, even though BEN alone 
showed a very weak acetylation effect. A recent study reported the synergistic histone 
acetylation when treating lymphoma cells with bendamustine and the HDACi romidepsin 
together, leading to an increased toxicity, but the underlying mechanisms behind this effects are 
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still unknown [41]. Common alterations affecting genes that play a role in epigenetic regulation 
have been recently described in DLBCL, such as those affecting the HATs CREBBP and 
EP300, that are known to be mutated in a 32% of DLBCLs [42-44]. Mutant forms of these two 
genes have been shown to cause an impaired acetylation that may contribute to 
lymphomagenesis by over-expression of the main DLBCL-related oncogene BCL6 and 
inactivation of p53 [45,46]. Inactivating mutations in EP300 and/or CREBBP are known to affect 
the HAT function of SU-DHL-6 and OCI-Ly19 cells whereas RC-K8 presents a well 
characterized rearrangement in EP300 [45,47]. As we have demonstrated in this study, VOR 
and more powerfully BEN plus VOR combination, enhanced histone acetylation in these 
defective cells. Thus, the use of VOR and BEN combined could potentially revert this situation 
as part of their anti-lymphoma mechanisms.  
One fifth of all DLBCL patients harbor somatic mutations in the TP53 gene, which correlate with 
poor survival to R-CHOP standard treatment, even within GCB and ABC subtypes [21]. The p53 
protein is a crucial tumor suppressor that mediates cell-cycle arrest, DNA repair, apoptosis, 
senescence and autophagy in response to cellular stress [48]. In order to explore the role of the 
TP53 mutational status in the BEN and VOR combination treatment, two out of the four cell 
lines used in this study carried deleterious TP53 mutations. In our case, TP53 mutational status 
did not correlate with differences in viability and apoptosis after BEN and VOR exposure, which 
implies that both drugs are effective in DLBCL cells independently of the TP53 mutational 
status. However, p53 protein levels were differentially modulated according to TP53 status and 
to the cytotoxic treatment, revealing that different mechanisms of apoptosis may be driving the 
cytotoxic effect in each situation. BEN exposure resulted in an increase of p53 protein levels 
and p21 upregulation only in the TP53-wild type cell lines, meaning that the cytotoxicity 
observed in cells with a nonfunctional p53 involved p53-independent mechanisms, such as the 
previously postulated mitochondrial oxidative stress or mitotic catastrophe [3,49]. On the other 
hand, it is well described that wild type p53 is not necessary for HDACis induced apoptosis [50], 
since cell cycle arrest through p53-independent induction of p21 is a major mechanism of VOR 
induced cytotoxicity [10,34,51]. In our experiments, VOR decreased the expression p53 in all 
cases, but only GCB cells had increased p21 expression, further correlating with the higher 
cytotoxic achieved effects. Intermediate amounts of p53 and cleaved PARP were seen in the 
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BEN plus VOR combination treatment, corroborating that HDACis and p53-activating agents 
may cause p53 antagonistic regulation in wild type-p53 cells, rather than increase the antitumor 
efficacy [50]. However, increased levels of p21 expression were maintained, and DNA damage 
levels, histone acetylation and apoptosis were enhanced, meaning that opposed regulation of 
p53 is overcome by these and potentially other mechanisms. Published data indicate that 
sensitivity of NHL cells to treatment with HDACis is dependent on the complex regulation of 
BCL-2 antiapoptotic family members, that includes the accumulation of MCL-1 as well as other 
inhibitors of apoptosis and the downregulation of BCL-X, among others [31,52,53], The 
accumulation of antiapoptotic regulators would cause a decrease in the apoptosis levels, 
whereas the drop of BCL-X after HDACi treatment has been described to activate the apoptosis 
inducing factor (AIF)-dependent apoptotic pathway, that is independent of caspase activation 
and PARP cleavage [54]. These two events, which we have also observed in our cells (data not 
shown) could explain the reduction of p53 and cleaved PARP without compromising cytotoxic 
effects. 
In summary, we have demonstrated that the pan-HDAC inhibitor VOR potentiates the BEN-
induced cytotoxicity in both GCB and ABC-DLBCL cells, independently on their TP53-
mutational status. Given the favorable toxicity profiles of both drugs, their distinctive mechanism 
of action and the favorable perspective of new drug combination approaches, the combination 
of BEN and VOR may be promising for the management of DLBCL patients with relapsed or 
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Table I.  Characteristics of DLBCL cell lines and primary cells. 






2.5 µM (%) 
Bliss  independence a 
bendamustine IC 50 
+vorinostat 2.5 µM 




75 61.7 0.107 ± 0.030 




50 31.1 0.041 ± 0.066 
Tumor sample #1 GCB wt 25† 41.5c - 
Tumor sample #2 ABC wt 25† 59.6c - 
 
aDifference between observed and predicted cytotoxic effect according to the Bliss model and 
confidence interval 
bWild type 






Figure 1. Bendamustine and vorinostat exert cytotox icity in GCB and ABC-DLBCL cells, 
independently of their TP53 mutational status. U-2932, RC-K8, SU-DHL-6 and OCI-Ly19 
cells were treated with increasing concentrations of bendamustine (5,25, 50, 100 µM) or 
vorinostat (1, 2.5, 5 µM) during 48 h. Cells were analyzed by FACS following staining with 
annexin-V/DAPI. The percentage of viable cells was normalized considering untreated control 
cells viability at 48h as 100%. 
 
Figure 2. Combined treatment of bendamustine and vo rinostat increases their cytotoxic 
effect as single agents. Apoptotic cells where determined by annexin-V/DAPI staining in three 
independent experiments. Mean percentages of unviable cells ± SEM are represented. *p<0.05, 
**p<0.01, NS: non-significant. (A) OCI-Ly19, SU-DHL-6, RC-K8 and U-2932 cells where treated 
with bendamustine (IC50), vorinostat (2.5 µM) or their combination during 48h. (B) DLBCL 
primary cells were treated with bendamustine (IC50), vorinostat (1 µM) or their combination 
during 24h.  
 
Figure 3. Bendamustine and vorinostat combination e nhances DNA damage and histone 
H3 acetylation. Cells were treated with VOR at 2.5 µM and BEN at 100 µM (5 µM of BEN in 
OCI-Ly19 cells, which had shown a greater sensitivity) during 48h. Western blot analyses of 
cleaved PARP, phosphorylated H2A.X and acetylated histone H3 were performed on the cell 
lysates from the four cell lines. The levels of β-actin served as loading control. 
 
Figure 4. Bendamustine and vorinostat trigger cytot oxic response in a different manner. 
After exposition to the indicated doses, p53 (A) and p21WAF1/CIP1 (B) expression were assessed 
by western blot and quantitative PCR, respectively. Three independent experiments were 
performed. Western blot results shown are representative of three independent experiments. 
For the quantitative PCR assay, average percentages ± SEM are represented. *p<0.05, 
**p<0.01. 
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